NYLIM
SAGE

New York Life Investment Management’s Sage Therapeutics SAGE Stock Holding History

New York Life Investment Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-19,151
Closed -$359K – 1232
2024
Q1 		$359K Buy
+19,151
New +$442K ﹤0.01% 1232

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

New York Life Investment Management's SAGE Position: Q2 2024 in Review

New York Life Investment Management sold out of Sage Therapeutics (SAGE) in Q2 2024, closing a stake of 19,151 shares — an estimated $359K sold.

New York Life Investment Management first reported a position in SAGE in Q1 2024 and held it in 1 quarter. The position peaked at $359K in Q1 2024. 194 funds tracked by Wall St. Rank hold SAGE as of Q2 2024.

  • New York Life Investment Management reported no remaining Sage Therapeutics position as of Q2 2024 after selling out during the quarter.
  • New York Life Investment Management sold 19,151 Sage Therapeutics shares in Q2 2024, an estimated $359K.
  • New York Life Investment Management first reported a position in Sage Therapeutics in Q1 2024 and held it in 1 quarter.
  • New York Life Investment Management's Sage Therapeutics position peaked at $359K in Q1 2024.
  • 194 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2024.

Based on New York Life Investment Management's 13F filing for Q2 2024, filed 5 Aug 2024.